Close

Drug Research

BioMed X and Merck KGaA, Darmstadt, Germany launch new research program in oncology

BioMed X, a leading independent research institute, announced the start of its eighth joint research program with Merck KGaA, Darmstadt, Germany. The new program will explore the role of extrachromosomal DNA in cancer and it will complement the research...

Recipharm signs Memorandum of Understanding (MOU) for the fill finish of vaccines and biotherapeutics in Morocco

Global contract development and manufacturing organisation (CDMO), Recipharm, has signed an MOU, along with His Majesty the King of Morocco, Mohammed VI, the Moroccan Government and a consortium of the country’s leading banks, that will see the company operate...

GSK and Alector to develop antibodies for neurodegenerative diseases

GlaxoSmithKline plc and Alector announced a strategic global collaboration for the development and commercialisation of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels. PGRN is a key regulator of immune activity in...

Pharma Majors Collaborate for Clinical Trial of Investigational Oral Anti-Viral Drug Molnupiravir for COVID-19

Cipla Limited, Dr. Reddy’s Laboratories Ltd., Emcure Pharmaceuticals Limited, Sun Pharmaceutical Industries Limited, and Torrent Pharmaceuticals Limited, announced that the five companies will collaborate for the clinical trial of the investigational oral anti-viral drug Molnupiravir for the treatment of...

Sanofi launches dedicated vaccines mRNA Center of Excellence

Sanofi will invest approximately €400 million annually in a first-of-its kind vaccines mRNA Center of Excellence. The Center will work to accelerate the development and delivery of next-generation vaccines by bringing together approximately 400 dedicated employees integrating end-to-end mRNA...

Roches Actemra/RoActemra receives U.S. FDA EUA for the treatment of COVID-19 in hospitalised adults and children

Roche announced that the U.S. FDA has issued an EUA for intravenous Actemra/RoActemra® (tocilizumab) for the treatment of COVID-19 in hospitalised adults and paediatric patients (two years of age and older) who are receiving systemic corticosteroids and require supplemental...

Fujitsu Japan Embarks on Joint Research for COVID-19 Therapies Using Fugaku

Fujitsu Japan Limited announced that it will initiate a new research project with a research team led by Takefumi Yamashita, Project Associate Professor of Research Center for Advanced Science and Technology (RCAST) , the University of Tokyo utilizing the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read